Caplin Point Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Caplin Point Laboratories Ltd reported a 9.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 19.0%.
• Its expenses for the quarter were up by 11.4% QoQ and 18.1% YoY.
• The net profit increased 4.2% QoQ and increased 19.0% YoY.
• The earnings per share (EPS) of Caplin Point Laboratories Ltd stood at 22.31 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Caplin Point Laboratories Ltd is a pharmaceutical company known for its focus on developing, manufacturing, and marketing a diverse range of pharmaceutical products. The company's primary offerings include generic formulations, branded generics, and over-the-counter (OTC) products. Caplin Point Laboratories serves both domestic and international markets, with a significant presence in Latin America, Africa, and South-East Asia. The company is involved in the entire value chain of pharmaceuticals, from product development to distribution. As per the last known public information, Caplin Point Laboratories has been investing in expanding its research and development capabilities and its manufacturing infrastructure to enhance its product portfolio and market reach. No recent major developments are available beyond the data provided.

Revenue

For the fourth quarter of fiscal year 2026 (Q4FY26), Caplin Point Laboratories Ltd reported a total income of ₹628.52 crores. This marks a quarter-over-quarter (QoQ) increase of 9.0% from ₹576.45 crores in the third quarter of fiscal year 2026 (Q3FY26). Year-over-year (YoY), the company's total income grew by 19.0% from ₹528.19 crores in the fourth quarter of fiscal year 2025 (Q4FY25). This consistent growth in revenue reflects the company's ongoing ability to enhance its market presence and product distribution. The increase in total income both QoQ and YoY suggests a positive trajectory in the company's sales and revenue-generating activities over the periods compared.

Profitability

Caplin Point Laboratories Ltd's profitability metrics for Q4FY26 indicate a Profit Before Tax (PBT) of ₹213.44 crores, reflecting a 4.7% QoQ growth from ₹203.91 crores in Q3FY26. Compared to Q4FY25, the PBT increased by 20.9% from ₹176.59 crores. The company reported a Profit After Tax (PAT) of ₹172.88 crores for Q4FY26, which is a 4.2% increase from ₹165.86 crores in Q3FY26 and a 19.0% increase from ₹145.28 crores in Q4FY25. The tax expense for Q4FY26 was ₹40.56 crores, illustrating a 6.7% increase QoQ and a 29.2% increase YoY. The Earnings Per Share (EPS) for Q4FY26 stood at ₹22.31, up by 3.7% from ₹21.51 in Q3FY26 and by 19.4% from ₹18.69 in Q4FY25. These metrics reflect a solid profitability performance over the reviewed periods.

Operating Metrics

The total expenses for Caplin Point Laboratories Ltd in Q4FY26 were ₹415.08 crores, showing an 11.4% increase from ₹372.54 crores in Q3FY26 and an 18.1% increase from ₹351.60 crores in Q4FY25. The increase in expenses aligns with the growth in revenue, potentially indicating investments in operational capacities and market expansion. The company's profitability margins, illustrated by consistent growth in both PBT and PAT, suggest effective management of cost structures despite increasing expenses. The EPS growth further underscores the company's ability to deliver shareholder value, with the YoY and QoQ increases suggesting efficient operational performance. These operating metrics provide insights into the company’s financial health and operational efficiency over the given periods.